Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer

Immunocore Andrew Hotchkiss

Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, has appointed Andrew Hotchkiss as Chief Commercial Officer. Andrew joins Oxford-based Immunocore from Eli Lilly & Co.